184 related articles for article (PubMed ID: 38481998)
1. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 CAR-T cells bridging to haploidentical stem cell transplantation.
Song Y; Liu Z; Wang Q; Gao K; Wu T
Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
[TBL] [Abstract][Full Text] [Related]
2. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy.
Li Z; An N; Yang K; Meng F; Xu T; Peng X; Wen X; Li J; Song Y; Yang R; Wu T
Transplant Cell Ther; 2023 Mar; 29(3):167-173. PubMed ID: 36427783
[TBL] [Abstract][Full Text] [Related]
3. CD7 CAR T bridging to allo-HSCT in R/R T-ALL: A case report.
Fanqiao M; Chen X; Ren X; Li L; Wu T
Pediatr Transplant; 2024 May; 28(3):e14367. PubMed ID: 35860981
[TBL] [Abstract][Full Text] [Related]
4. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
5. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
6. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
9. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
10. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
11. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H
N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244
[TBL] [Abstract][Full Text] [Related]
12. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
[TBL] [Abstract][Full Text] [Related]
13. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
Xie L; Ma L; Liu S; Chang L; Wen F
Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
[TBL] [Abstract][Full Text] [Related]
15. [CAR T-cell bridging to allo-HSCT for relapsed/refractory B-cell acute lymphoblastic leukemia: the follow-up outcomes].
Yan M; Wu YJ; Chen F; Tang XW; Han Y; Qiu HY; Sun AN; Xue SL; Jin ZM; Wang Y; Miao M; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):710-715. PubMed ID: 33113601
[No Abstract] [Full Text] [Related]
16. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
17. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
18. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
Front Immunol; 2022; 13():934442. PubMed ID: 36110859
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
[TBL] [Abstract][Full Text] [Related]
20. Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: A Case Report.
Han Y; Yao H; He GC; Lai SH; Deng Y; Zhang S; He Y; Xiong YS; Chang AH; Su Y; Yi H
Front Immunol; 2023; 14():1254010. PubMed ID: 37841245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]